Adverse events as N of participants with at least one adverse event objective · patients with schizophrenia
It is very uncertain whether haloperidol changes adverse effects: number of participants with at least one adverse… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal side effects: number of participants with at least one extrapyramidal side effect (medium term) · patients with schizophrenia
It is very uncertain whether haloperidol changes adverse effects: extrapyramidal side effects: number of participants… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
Haloperidol showed no clear difference in leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (low certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether haloperidol changes leaving the study early due to inefficacy of treatment as a measure… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia
It is very uncertain whether haloperidol changes leaving the study early due to adverse events as a measure of… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with schizophrenia
Haloperidol showed no clear difference in adverse effects: number of participants with at least one adverse… compared with first‐generation antipsychotics (low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether haloperidol changes adverse effects: extrapyramidal side effects: number of participants… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Response to treatment (medium term) Clinically important response to treatment as defined by each study · patients with schizophrenia
Haloperidol may leads to lower clinically important response to treatment (medium term) compared with first‐generation antipsychotics (low certainty).
1 finding from 1 review
Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia
It is very uncertain whether haloperidol changes leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with schizophrenia
1 finding from 1 review
Clinical response to treatment · patients with schizophrenia
HALOPERIDOL showed no clear difference in clinical response to treatment compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
HALOPERIDOL showed no clear difference in leaving the study early ‐ Due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with schizophrenia
It is very uncertain whether HALOPERIDOL changes adverse effects ‐ at least one adverse effect compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).
1 finding from 1 review
Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia
HALOPERIDOL may leads to higher adverse effects ‐ movement disorders ‐ At least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
HALOPERIDOL probably leads to lower adverse effects ‐ other ‐ Sedation compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
1 finding from 1 review
Death · patients with schizophrenia
1 finding from 1 review
Quality of life · patients with schizophrenia
1 finding from 1 review
Death: Suicide and natural causes (no data) · patients with schizophrenia
1 finding from 1 review
Global state: no overall improvement (psychiatrist ‐ rated) · patients with schizophrenia
HALOPERIDOL probably leads to lower overall improvement: No marked global improvement Rated by clinician compared with PLACEBO (moderate certainty).
1 finding from 1 review
Not discharged from hospital · patients with schizophrenia
It is very uncertain whether HALOPERIDOL changes not discharged from hospital compared with PLACEBO (very low certainty).
1 finding from 1 review